MedTrace Logo

Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain

NCT02820519 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-07-01

No results posted yet for this study

Summary

Loxapine is an antipsychotic drug approved for the treatment of schizophrenia in several countries including the United States. In animal studies in mice, loxapine reduced neuropathic pain. Hence, in a proof-of-principle and dose-escalating study the tolerability and analgesic efficacy of loxapine will be evaluated in patients with neuropathic pain.

Conditions

  • Neuropathic Pain

Interventions

DRUG

Loxapine

Loxapine dose escalation according to tolerability and analgesic efficacy

Sponsors & Collaborators

  • University of Witten/Herdecke

    lead OTHER

Principal Investigators

  • Sven Schmiedl, MD · Witten/Herdecke University

  • Sven Schmiedl, MD · HELIOS Clinic Wuppertal

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-07
Primary Completion
2017-05-04
Completion
2017-05-04

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02820519 on ClinicalTrials.gov